Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion

European Journal of Medical Research

Volumn 11, Issue 7, 2006, Pages 273-278

  Vogel, M ^a   Lichterfeld, M ^b   Kaufmann, D E ^b   Mui, S K ^b   Altfeld, M ^b   Voigt, E ^a   Ahlenstiel, G ^a   Kupfer, B ^a   Walker, B ^b,c   Spengler, U ^a   Rockstroh, Jürgen K ^a  

^a UNIVERSITY OF BONN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

HAART; HIV 1; Investigational therapies; Primary HIV 1 infection; Structured treatment interruption

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPHOCYTE COUNT; MALE; SEROCONVERSION; VIRUS IMMUNITY; VIRUS INHIBITION;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY TESTING; HIV SEROPOSITIVITY; HIV-1; HUMANS; LAMIVUDINE; MALE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RNA, VIRAL; STAVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 33747226141     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 2002;99(21):13747-52.
2. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003;163(10):1220-6.
3. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407(6803):523-6.
4. Lori F, Lewis MG, Xu J, et al. Control of SW rebound through structured treatment interruptions during early infection. Science 2000;290(5496):1591-3.
5. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340(21):1683-4.
6. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278(5342):1447-50.
7. Lichterfeld M, Kaufmann DE, Yu XG, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004;200(6):701-12.
8. Younes SA, Yassine-Diab B, Dumont AR, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003;198(12):1909-22.
9. Lichterfeld M, Yu XG, Cohen D, et al. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. Aids 2004;18(10):1383-92.
10. Hess C, Altfeld M, Thomas SY, et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004;363(9412):863-6.
11. Yu XG, Addo MM, Rosenberg ES, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002;76(17):8690-701.
12. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004;1(2):e36.
13. Nischalke HD, Nattermann J, Lichterfeld M, et al. Rapid determination of the Delta32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by lightcycler real-time polymerase chain reaction. AIDS Res Hum Retroviruses 2004;20(7):750-4.
14. Lichterfeld M, Nischalke HD, van Lunzen J, et al. The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDS. Clin Immunol 2003;107(1):55-9.
15. Royo JL, Ruiz A, Borrego S, et al. Fluorescence resonance energy transfer analysis of CCR-V64I and SDF1-3′a polymorphisms: prevalence in southern Spain hiv type 1+ cohort and noninfected population. AIDS Res Hum Retroviruses 2001;17(8):663-6.
16. Brander C, Goulder P. The evolving field of HIV CRL epitope mapping: new approaches for the identification of novel epitopes. In: Korber B, Brander C, Walker B, et al., eds. HIV molecular database. Los Alamos, New Mexico: Los Alamos National Laboratory; 2000.
17. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000;97(6):2709-14.
18. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2(4):405-11.
19. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127(10):882-90.
20. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75(24):11983-91.
21. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3(11):1061-8.
22. Price DA, West SM, Betts MR, et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 2004;21(6):793-803.
23. Leslie AJ, Pfafferott KJ, Cherry P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004;10(3):282-9.